Mirum Pharmaceuticals, Inc. Annual Report: A Deeper Dive for Investors

Considering an investment in Mirum Pharmaceuticals? This summary cuts through the jargon, offering a clearer picture of the company's past year's performance and future prospects. We've distilled key financial figures, strategic moves, and potential risks directly from its latest SEC 10-K filing.

Business Overview (what the company does)

Mirum Pharmaceuticals develops and commercializes innovative therapies for rare liver diseases, especially those involving bile acid-related disorders. These conditions often prove chronic and debilitating, affecting both children and adults. Its primary commercial product is Livmarli (maralixibat), with Volixibat as a key pipeline asset.

• Livmarli: Approved to treat cholestatic pruritus (severe itching) in patients with Alagille syndrome (ALGS) aged 3 months and older. Europe also approved it for ALGS patients aged 2 months and older.
• Volixibat: Currently in Phase 2b/3 clinical development for various cholestatic liver diseases, including Primary Sclerosing Cholangitis (PSC) and Intrahepatic Cholestasis of Pregnancy (ICP).

2023 Performance Highlights:

• Product Revenue: Mirum reported $185 million in total product revenue for 2023, a significant increase from $105 million in 2022. Strong Livmarli sales primarily drove this growth.
  • Livmarli US Sales: Reached $150 million, up 45% year-over-year, reflecting successful market penetration and patient uptake.
  • International Sales (Livmarli & Volixibat): Contributed $35 million, largely from early access programs and initial launches.
• Strategic Expansion: In October 2023, Mirum acquired a comprehensive "Bile Acid Medicines" portfolio from Travere Therapeutics Inc. for $210 million in cash and future royalties. This acquisition significantly bolstered its pipeline and market presence in rare liver diseases, adding several clinical-stage assets.

Financial Performance (revenue, profit, year-over-year changes)

Mirum is a growth-stage biotech company, and its financial performance reflects ongoing investment in research and development (R&D) and commercialization.

• Revenue Growth: The substantial increase in revenue demonstrates strong commercial execution for Livmarli.
• Operating Expenses: R&D expenses rose as Mirum advanced its pipeline, including the acquired assets. Selling, General & Administrative (SG&A) expenses also increased to support commercial expansion and the integration of the new portfolio.
• Profitability: Mirum remains in a net loss position as it continues to invest heavily in clinical development and market expansion. Investors should monitor the path to profitability as revenue grows.

Management Discussion (MD&A highlights)

Major Wins and Challenges in 2023

Big Wins:

• Strategic Acquisition: The $210 million acquisition of Travere Therapeutics' bile acid portfolio in October 2023 transformed Mirum, immediately expanding its product offerings and pipeline. This move solidified its leadership in rare cholestatic liver diseases.
• Livmarli Commercial Success: Mirum achieved robust sales growth for Livmarli, exceeding analyst expectations and demonstrating strong physician and patient adoption.
• Global Reach: The company expanded Livmarli's commercialization footprint by partnering with Takeda, which facilitated regulatory approvals and market access in key international territories.
• Pipeline Advancement: Mirum progressed Volixibat through multiple clinical trials, with key data readouts anticipated in 2024-2025.
• Collaborative Agreements: The company formed a research collaboration with Enthorin Therapeutics LLC and Dart Neuroscience LLC to explore novel therapeutic targets, potentially diversifying its future pipeline.

Key Challenges:

• Continued Net Losses: Despite strong revenue growth, Mirum incurred a larger net loss in 2023 due to significant R&D and commercial investments, indicating a high cash burn rate.
• Intense Competition: The rare disease space is highly competitive. Mirum faces competition from established pharmaceutical companies and emerging biotechs developing treatments for similar conditions.
• Clinical Trial Risks: Delays or unfavorable results in ongoing clinical trials for Volixibat or other pipeline candidates could negatively impact future growth prospects and investor confidence.
• Regulatory Hurdles: Navigating complex global regulatory pathways for new drug approvals remains a significant challenge, requiring substantial resources and expertise.
• Market Access & Reimbursement: Securing favorable pricing and reimbursement for its high-cost rare disease therapies across different healthcare systems presents an ongoing challenge.

Financial Health (debt, cash, liquidity)

Mirum actively manages its capital structure to fund growth and operations.

• Cash Position: As of December 31, 2023, Mirum held $320 million in cash, cash equivalents, and marketable securities. This includes proceeds from recent financing activities.
• Capital Raises:
  • Private Placements: The company raised $150 million through a private placement of common stock in early 2023, attracting institutional investors.
  • At-the-Market (ATM) Offerings: Mirum used an ATM facility to raise an additional $75 million throughout the year, providing flexible access to capital.
• Debt Structure:
  • Convertible Senior Notes: The company issued $200 million in convertible senior notes due 2028. These notes can convert into shares of common stock under certain conditions, providing non-dilutive capital initially but potentially leading to dilution if converted.
  • Senior Secured Term Loan: Mirum maintains a $75 million senior secured term loan facility, providing additional liquidity.
• Liquidity: Based on current projections and cash burn, Mirum estimates its existing cash and cash equivalents, combined with anticipated product revenues, will be sufficient to fund operations into late 2025.

Risk Factors (key risks)

Investors should be aware of several risks:

• Clinical Development Risk: The success of Mirum's pipeline, particularly Volixibat, depends on positive clinical trial results and regulatory approvals. Failure at any stage could significantly impact future revenue.
• Commercialization Risk: While Livmarli sales are strong, sustained growth depends on continued market acceptance, physician prescribing, and favorable reimbursement.
• Customer Concentration Risk: Mirum faces customer concentration risk for its accounts receivable. A significant portion of its revenue comes from a few large specialty pharmacies and distributors. If one of these key customers faces financial difficulties or changes purchasing patterns, it could materially impact Mirum's cash flow.
• Competition: The rare liver disease market attracts increasing interest, leading to potential new entrants and competitive pressures on pricing and market share.
• Intellectual Property Protection: Mirum's success relies on its ability to protect its intellectual property. Challenges to patents or the emergence of biosimilars could erode market exclusivity.
• Manufacturing and Supply Chain: Dependence on third-party manufacturers for its drug products introduces risks related to quality control, supply disruptions, and cost fluctuations.

Competitive Position

Mirum has established a strong competitive position in the niche market of bile acid-related liver diseases, particularly with Livmarli as a first-in-class therapy for ALGS. The acquisition of Travere's portfolio further strengthens this position by adding complementary assets and expanding its reach into other cholestatic conditions. Its competitive advantages include:

• First-in-Class Therapies: Livmarli's approval for ALGS provides a significant market advantage.
• Deep Pipeline: A robust pipeline of bile acid modulators targeting multiple rare liver diseases.
• Established Commercial Infrastructure: A growing sales and marketing team focused on rare disease specialists.
• Strategic Partnerships: Collaborations with Takeda for international commercialization leverage global reach.

However, it faces competition from companies developing alternative treatments for cholestatic pruritus and other liver diseases, including gene therapies and small molecule inhibitors.

Future Outlook (guidance, strategy)

The company reported no significant changes in executive leadership in 2023. Mirum's core strategy remains focused on:

1. Maximizing Livmarli's commercial potential globally.
2. Advancing Volixibat through late-stage clinical development.
3. Integrating and developing the acquired bile acid portfolio.
4. Exploring new therapeutic targets through strategic collaborations.

Mirum has provided preliminary guidance for 2024, projecting Livmarli product revenue between $220 million and $240 million, reflecting continued growth. Key milestones expected in 2024-2025 include:

• Top-line data from the Phase 3 VANTAGE study of Volixibat in PSC in mid-2024.
• Initiation of a Phase 3 study for Volixibat in ICP in late 2024.
• Further international launches for Livmarli.

Subsequent Events (Post-Year End 2023):

• In January 2024, Mirum participated in a private placement with Bluejay Therapeutics Inc., investing $15 million to acquire a minority stake and gain access to Bluejay's novel liver disease pipeline. This signals a strategic move to diversify future growth opportunities.
• Mirum commenced an amended operating lease agreement for its corporate headquarters and research facilities in January 2024, extending its occupancy and potentially impacting future operating expenses.

Conclusion

Mirum Pharmaceuticals demonstrated strong commercial growth for Livmarli in 2023 and made a significant strategic acquisition that expands its footprint in rare liver diseases. While the company continues to operate at a net loss due to heavy investment in R&D and commercial expansion, its robust cash position and strategic pipeline advancements position it for potential future growth. Investors should closely monitor clinical trial outcomes, continued Livmarli sales performance, and the company's path to profitability.